Themis Bioscience GmbH, of Vienna, said it closed a series C financing totaling €10 million (US$12.1 million) led by Global Health Investment Fund (GHIF), with participation from current investors, including aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences. Glenn Rockman, partner at GHIF, will join Themis' supervisory board.